This document is a regulatory filing submitted by Dr. Reddy's Laboratories Ltd. to the BSE Surveillance department. It is a clarification issued in response to a query from BSE Limited dated July 28, 2026, regarding a news article published in Business Standard on the same date.
The news article in question had the headline "Dr Reddys antibiotic gets Thailand approval six months after US nod". The company confirms that the headline is correct. The news pertained to a joint press release issued by the company and the Global Antibiotic Research & Development Partnership Foundation ("GARDP") on July 27, 2026. The press release was titled "Thai FDA approves NUZOLVENCE® (zoliflodacin) just six months after US authorization."
The company explicitly states that this matter, the Thailand approval of the drug NUZOLVENCE® (zoliflodacin), does not constitute a material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations. The letter reiterates that the company makes timely disclosures of all material events in compliance with these regulations.
The letter is signed by K Randhir Singh, who holds the positions of Company Secretary, Compliance Officer and Head-CSR for Dr. Reddy's Laboratories Limited. It was digitally signed on July 29, 2026, at 10:35:39 IST.